A key finding is the role of VCAN as an m6A-driven oncogene. m6A modifications on VCAN mRNA recruit IGF2BP proteins to stabilize transcripts and enhance translation, aiding tumor growth and metastasis. Using programmable dCasRx/METTL3 editing,2 we demonstrated that elevating VCAN m6A levels directly enhances invasiveness—a result with therapeutic implications. Outside of VCAN, germline polymorphisms such as rs4951018 act as m6A quantitative trait loci (m6A-QTLs) and correlate with SLC45A3 mRNA and protein levels. Aligns with this observation, a recent study by Lan, Y. et al introduces synonymous mutations that disrupt m6A patterns and consequently affect mRNA metabolism.3 This interplay between inherited variants and somatic alterations highlights m6A’s role as a molecular bridge linking genetic risk to tumor evolution.
Clinically, m6A offers a prognostic value for prostate cancer, suggesting the potential for post-surgical monitoring. Methodologically, our HistogramZoo algorithm and refined meRIP-seq protocol enable robust m6A profiling even in low-input samples. These advances pave the way for future epitranscriptomic studies. Key questions are still outstanding. How are m6A landscapes remodeled in metastasis, and might they predict resistance to therapy? How the mechanisms connecting hypoxia to m6A dysregulation work are also worth further exploration—does hypoxia affect methyltransferase function directly, or does it regulate RNA-binding protein interactions? Elucidating this might reveal microenvironmental therapeutic weaknesses.
In summary, m6A emerges as a new focal point in prostate cancer biology, influencing everything from inherited risk to metastatic growth. Integrating m6A profiling into clinical workflows could refine risk stratification, while therapies targeting its writers, readers, or erasers, complemented by strategies directly targeting functional m6A sites, may open new avenues for precision medicine.
Written by:
- Housheng Hansen He, PhD, Princess Margaret Cancer Center, University Health Network; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
- Xin Xu, MD, PhD, Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
- Xu, X. et al. The landscape of N6-methyladenosine in localized primary prostate cancer. Nat. Genet. (2025) doi:10.1038/s41588-025-02128-y.
- Xia, Z. et al. Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylase. Nucleic Acids Res. 49, 7361–7374 (2021).
- Lan, Y. et al. Synonymous mutations promote tumorigenesis by disrupting m6A-dependent mRNA metabolism. Cell (2025) doi:10.1016/j.cell.2025.01.026.